Innoskel (Biotechnology, Health and Wellness) — Funding, Investors & Signals 2026

Innoskel

Developing novel therapies for rare bone diseases

Founded 2020 France

France 2 employees Series A Total: $20.00M Biotechnology, Health and Wellness

Innoskel is a biotechnology startup with the slogan "Developing novel therapies for rare bone diseases." Founded in 2020 and headquartered in France, the company is focused on developing therapies for rare bone diseases, particularly targeting type 2 collagenopathies, including Spondyloepiphyseal Dysplasia congenita (SEDc), which is the second leading cause of dwarfism worldwide. Innoskel’s lead gene therapy asset for SEDc has shown promising efficacy in proof-of-concept studies. The company's last investment was a €20.00M Series A investment on 14 December 2020, with participation from Jeito Capital, Turenne Capital, Vida Ventures, and Région Sud Investissement. Innoskel's fundamental mission revolves around improving the lives of patients living with rare bone disorders, with a focus on addressing their unmet needs and placing their voices at the heart of all strategic decisions. The startup operates within the Biotechnology and Health and Wellness industries, aiming to make a significant impact in the field of rare bone disease therapies.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	••••••	4		14 Dec 2020

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

••••••

14 Dec 2020

FAQ About Innoskel

Developing novel therapies for rare bone diseases

Innoskel was founded in 2020.

Innoskel is headquartered in France.

Innoskel operates in the following industries: Biotechnology, Health and Wellness.

Innoskel has approximately 2 employees.

Innoskel has completed 1 funding round, raising a total of $20.00M. The latest funding stage is Series A.

Innoskel offers: Online retail of a wide range of products including electronics, fashion, beauty and health, home and lifestyle, sports and outdoor, automotive, gaming, electronics accessories, media and books, and food and beverages..

Top alternatives and competitors to Innoskel include Enobia Pharma, de Duve Institute, Praxis Precision Medicines, Inc., Apic Bio, Initiate. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Innoskel and Enobia Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Innoskel

General Information

Track Innoskel

Discover More

About Innoskel

Services & Products

Target Customers

Funding Rounds & Investors (1)

Innoskel Alternatives & Competitors

FAQ About Innoskel

Don't just browse. Track.